Researchers at the University of Luebeck have revealed the structure of the IMP dehydrogenase, a central target of T. brucei, which causes sleeping sickness.
Scientists at Imperial College London have created a worldwide atlas of dengue virus transmission with much higher spatial resolution than any previous regional- or global-scale estimates.
The ENABLE project has achieved its initial goals to identify three antibacterial leads, select two antibacterial development candidates and advance one compound into Phase I development.
Bionetix, ProQinase, and MercachemSyncom have announced that they will jointly develop a new AML drug, from target identification to clinical testing
Merck KGaAs 2017 Swiss cancer spin-out iOnctura SA has raised 15m to bring its PI3K? inhibitor and autotaxin inhibitor to the clinic.
mRNA cancer neoantigen specialist BioNTech AG is set to buy all shares of Neon Therapeutics, Inc. expanding its pipeline of neoantigen-targeting therapies and getting foothold in the US.
British researchers have identified several small molecule drugs that sensitized B cell cancers to chemotherapy and extended survival in mouse models.
Adaptimmune Therapeutics plc and Japanese Astellas Pharma, Inc. have signed a discovery partnership to develop off-the-shelf allogeneic T cell-based cancer therapies from stem cells.
Twelve years after Roches $6.8bn hostile takeover bid for Illumina, the companies have entered into a 15-year partnership to boost personalised NGS-based cancer testing.